Migraine News
-
Histoplasmosis Infection Risks for Workers & Vulnerable Populations
ScienceNews published an article last year about the spread of three types of fungi that can cause serious lung diseases. One of these was Histoplasma which causes histoplasmosis, an infection once mainly found in the Midwest, but in more recent times infections have been recorded in at least 47 states. Histoplasma capsulatum lives in the environment, particularly in soil or other materials ...
-
Histoplasma Infection Risks for Workers and Vulnerable Populations in Puerto Rico
Histoplasmosis is the name of an infection caused by a fungus known as Histoplasma capsulatum. The fungus lives in the environment, particularly in soil or other materials that contain large amounts of bird or bat droppings. Outbreaks of histoplasmosis have been recorded in Puerto Rico, as well as in the Dominican Republic and other parts of the Caribbean. The Centers for Disease Control and ...
-
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
Orginally published by https://www.globenewswire.com/ Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate efficacy of the company’s single-dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. Emergent will begin the planning phase, the first ...
-
electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within selected managed care health systems. ...
-
XPhyto Files Patent Application for Library of Novel Psychedelic Compounds
XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report that it has filed a patent application for a significant library of novel psychedelic compounds. Each compound was designed to provide specific alterations in their respective biopharmaceutical properties. The library of compounds can be selected to target ...
-
When Contact Sports Cause Concussion Injuries, Who Comes Out Ahead?
In a 15-year retrospective study (here) of 1,200 varsity student-athletes at Columbia University in New York, Dr. James Noble, NoMo Diagnostics CMO, found: the most commonly reported concussion symptoms include headache, impaired concentration, and dizziness; the risk of concussion was higher among females (23.3 percent) than males (17 percent) over the course of their collegiate career; and the ...
-
Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult patients with major depressive disorder (MDD) and postpartum depression. The 11 new analyses are being presented at the 2022 Psych Congress in New Orleans, ...
-
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. Under the terms of the agreement, $50 million is ...
-
FireGene's Monkeypox Virus Nucleic Acid Detection Kit (Real-time PCR Method) Receives CE-IVDD Certification
FireGene announces that its Monkeypox Virus Nucleic Acid Detection Kit (Real-time Fluorescent PCR Method) has recently obtained CE-IVDD approval. This RT-PCT kit can be used to detect suspected cases of MPV infection. Rash fluid, nasopharyngeal swabs, pharyngeal swabs, and serum samples are applicable for the test. The test result is available in 40 minutes after sample collection. This kit is ...
By FireGene
-
FDA-Approved Cefaly Device to Stop Migraines Now Available
Renowned for helping prevent migraine attacks, a new FDA clearance paves way for more Cefaly devices that can now stop a migraine in progress and prevent a future episode too. CEFALY Technology announces today the release of two new U.S. Food and Drug Administration (FDA)-cleared migraine treatment devices. Cefaly®, already the first FDA-approved external trigeminal nerve stimulation (e-TNS) ...
By CEFALY
-
Neurolief’s Digital Therapeutics Neuromodulation System May Challenge Medication Therapies for the Treatment of Migraine
Neurolief, a neurotechnology innovator, today announces the publication of the SP301 study in the Pain and Therapy Journal that demonstrates the safety and efficacy of Relivion MG, Neurolief’s CE-marked and FDA cleared wearable neuromodulation system for at-home treatment of migraine with remote physician monitoring. The study is the first to prove that external concurrent stimulation of ...
-
Peer-Reviewed Published Study Provides Further Evidence for the Safety and Efficacy of Nerivio in Patients with Chronic Migraine
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today a new peer-reviewed article, with the publication of a chronic migraine study by Pain Reports. The prospective, multi-center, open-label trial (NCT04194008), evaluated the efficacy and safety of remote electrical neuromodulation (REN) for the acute ...
-
NeuroSigma Continues to Build a Substantial Global Bioelectronics Patent Portfolio
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing trigeminal nerve stimulation (TNS) technology to treat neurological and neuropsychiatric disorders, announced today that the following patents have issued or received notices of allowance in Canada and Japan: Canadian patent no. 2776694 entitled Devices, Systems, and Methods for Treatment of Neuropsychiatric ...
-
Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced it has seen consistent growth in the usage of Nerivio, marking more than 100,000 treatments in the USA. "We are at a crossroads for acute migraine treatment, where traditional drug-based solutions are being challenged by FDA-authorized, novel digital ...
-
NeuroSigma Successfully Obtains HCPCS Codes from CMS for the Monarch eTNS System
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders, announces that the Centers for Medicare & Medicaid Services ("CMS") is establishing two new Level II Healthcare Common Procedure Coding System ("HCPCS") codes for the Monarch eTNS System®, effective ...
-
New respiratory multitest
The new Vitassay SARS-CoV-2 + Flu A + B + RSV + Adeno Resp. is a rapid, immunochromatographic assay for the simultaneous qualitative detection of nucleoprotein antigen of SARS-CoV-2, Influenza type A, Influenza type B, RSV and Adenovirus from nasopharyngeal swabs samples from patients suspected of COVID-19 infection and/or Influenza A and/or Influenza B and/or Respiratory Syncytial Virus (RSV) ...
-
New Vitassay Rapid Test for SARS-CoV-2 detection
The new Vitassay SARS-CoV-2 is a rapid, immunochromatographic, one step assay for the qualitative detection of SARS-CoV-2 from nasopharyngeal samples. Simple and highly sensitivity immunoassay for professional in vitro use only. SARS-CoV-2 infection can affect individuals of any age. The disease currently causes an overwhelming hospitalization of infected patients, presenting symptoms such as ...
-
Some Health Care Professionals in Puerto Rico at Risk of Exposure to Waste Anesthetic Gases
Waste anesthetic gases (WAGs) are small amounts of volatile anesthetic gases that leak from a patient’s anesthetic breathing circuit into the air of operating rooms during the delivery of anesthesia. These gases may also be exhaled by patients recovering from anesthesia. Waste anesthetic gases include both nitrous oxide and halogenated anesthetics. The Occupational Safety and Health ...
-
154 died of heat stroke in New York City from 2000-11: said CDC
Heat waves are the deadliest of extreme weather events, the Centers for Disease Control and Prevention reported this week. A case study published in the August 9 edition of the agency’s journal, Morbidity and Mortality Weekly Report, looked at heat illness in New York City from 2000 to 2011. The results revealed that there were more than 150 deaths, about 1,600 hospitalizations and around ...
-
Aurobindo Pharma receives USFDA Approval for Ibuprofen OTC Capsules
Aurobindo Pharma Limited is pleased to announce that the Company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Ibuprofen capsules OTC, 200mg. Aurobindo’s Ibuprofen capsules are a generic equivalent of Pfizer’s Advil Liqui-Gels Capsules. The product will be launched in Sep 2018. Ibuprofen is used to relieve pain from various conditions ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you